{"id":450,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"mapa-de-evidencia-sobre-el-estado-de-desarrollo-de-la-retatrutida-en-2026","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/retatrutide-development-status-2026-evidence-map\/","title":{"rendered":"Estado de desarrollo de Retatrutide en 2026: un mapa de evidencia para investigadores"},"content":{"rendered":"
Los compuestos en etapa de desarrollo crean un problema recurrente de precisi\u00f3n de SEO: los anuncios de pruebas, el estado del registro, los informes de conferencias, los art\u00edculos de revistas y las aprobaciones a menudo se combinan en una sola l\u00ednea de tiempo. Este mapa de evidencia mantiene esos hitos separados para la retatrutida.<\/p>
Conclusiones clave<\/h2>
Los resultados de la fase 2 revisados \u200b\u200bpor pares y un registro de registro 3 de la fase completa son objetos de evidencia diferentes.<\/li>
ClinicalTrials.gov todav\u00eda no muestra resultados publicados para TRIUMPH-1, mientras que ahora existen divulgaciones principales del patrocinador de 2026; esos objetos de evidencia se informan por separado a continuaci\u00f3n.<\/li>
El estado regulatorio debe compararse con los registros FDA, no inferirse de la cobertura de los medios o la disponibilidad del cat\u00e1logo.<\/li><\/ul><\/div><\/div>Ilustraci\u00f3n conceptual de la investigaci\u00f3n de m\u00faltiples receptores; no se muestra ning\u00fan resultado de prueba ni presentaci\u00f3n del producto.<\/figcaption><\/figure>
La escalera de la evidencia<\/h2>
Un registro de ensayos responde a preguntas sobre el protocolo y el estado: qu\u00e9 se plane\u00f3, qui\u00e9n era elegible, qu\u00e9 resultados se designaron y si el reclutamiento o el seguimiento est\u00e1n completos. Un art\u00edculo de revista responde a un conjunto diferente de preguntas despu\u00e9s del an\u00e1lisis de datos y la revisi\u00f3n por pares. Un registro de aprobaci\u00f3n FDA agrega una determinaci\u00f3n regulatoria independiente para un producto espec\u00edfico.<\/p>
Publicado<\/strong>Ensayo de fase 2 sobre obesidad con resultados revisados \u200b\u200bpor pares<\/span><\/div>
Registrado\/completado<\/strong>Registro TRIUMPH-1 fase 3; informaci\u00f3n de estado y protocolo<\/span><\/div>
Patrocinador reportado<\/strong>Resultados principales de la fase 2026 3; informes a\u00fan no completos revisados \u200b\u200bpor pares<\/span><\/div>
EnsayosCl\u00ednicos.gov<\/strong>TRIUMPH-1 todav\u00eda muestra No hay resultados publicados<\/span><\/div>
No establecido<\/strong>Aprobaci\u00f3n FDA para retatrutida<\/span><\/div><\/div><\/div>
C\u00f3mo actualizar esta p\u00e1gina de forma responsable<\/h2>
Cuando un registro cambia, registre la fecha de actualizaci\u00f3n y describa solo el campo modificado. Cuando aparezcan los resultados, vincule el registro de resultados o la publicaci\u00f3n revisada por pares y distinga los criterios de valoraci\u00f3n preespecificados de los an\u00e1lisis exploratorios. Cuando cambie el estado regulatorio, reemplace (no simplemente agregue) la declaraci\u00f3n de estado anterior.<\/p>
No actualice la fecha del art\u00edculo sin cambios sustanciales en la evidencia. La gu\u00eda de Google sobre las personas primero advierte expl\u00edcitamente contra el cambio de fechas s\u00f3lo para que el contenido parezca nuevo.<\/p>
L\u00ednea superior de Phase 3 informada por el patrocinador de 2026<\/h2>
Lilly inform\u00f3 los mejores resultados para TRIUMPH-1 en mayo 21, 2026: en las semanas 80, el patrocinador inform\u00f3 un cambio de peso medio de \u221228.3% para el grupo de mg de 12. En julio 23, 2026, Lilly inform\u00f3 cambios medios hasta \u221220.8% en TRIUMPH-2 y \u221222.6% en TRIUMPH-3. Estas son divulgaciones del patrocinador principal, no m\u00f3dulos de resultados de ClinicalTrials.gov ni informes completos revisados \u200b\u200bpor pares; Los m\u00e9todos detallados, las decisiones de an\u00e1lisis y las tablas completas de eventos adversos a\u00fan requieren registros completos. ClinicalTrials.gov continu\u00f3 mostrando \"No se publicaron resultados\" para TRIUMPH-1 en esta revisi\u00f3n.<\/p>
Implicaciones para las p\u00e1ginas de investigaci\u00f3n de cat\u00e1logos<\/h2>
Una p\u00e1gina de cat\u00e1logo puede utilizar el cronograma de desarrollo para orientar a los investigadores, pero debe mantener la separaci\u00f3n entre la evidencia bibliogr\u00e1fica y la calidad del lote. Debe vincularse a los m\u00f3dulos de evidencia y especificaciones de la familia, y debe indicar que el material no es para uso humano o veterinario.<\/p>","protected":false},"excerpt":{"rendered":"
Un mapa de evidencia 2026 que separa los datos publicados de la fase 2 de retatrutida, los registros del estudio 3 de la fase completa, los resultados no publicados y el estado regulatorio.<\/p>","protected":false},"author":1,"featured_media":620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Development-status evidence map","pim_evidence_level":"Trial registry, peer-reviewed phase 2 evidence and FDA status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Retatrutide phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Peer-reviewed outcomes.\"},{\"title\":\"TRIUMPH-1 ClinicalTrials.gov record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"Protocol and current study-status record.\"},{\"title\":\"FDA current information on retatrutide status\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Authoritative regulatory boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"},{\"title\":\"Google guidance on people-first content and substantive date changes\",\"url\":\"https:\/\/developers.google.com\/search\/docs\/fundamentals\/creating-helpful-content\",\"note\":\"Official Google Search Central guidance cited for the editorial-update statement.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD<\/title>\n<meta name=\"description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\" \/>\n<meta property=\"og:description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Estado de desarrollo de Retatrutide en 2026: un mapa de evidencia para investigadores - NHD","description":"Un mapa de evidencia 2026 que separa los datos publicados de la fase 2 de retatrutida, los registros del estudio 3 de la fase completa, los resultados no publicados y el estado regulatorio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/retatrutide-development-status-2026-evidence-map\/","og_locale":"es_ES","og_type":"article","og_title":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","og_description":"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.","og_url":"https:\/\/nhdbio.com\/es\/retatrutide-development-status-2026-evidence-map\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","url":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","name":"Estado de desarrollo de Retatrutide en 2026: un mapa de evidencia para investigadores - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Un mapa de evidencia 2026 que separa los datos publicados de la fase 2 de retatrutida, los registros del estudio 3 de la fase completa, los resultados no publicados y el estado regulatorio.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Development Status in 2026: An Evidence Map for Researchers"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=450"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/450\/revisions"}],"predecessor-version":[{"id":530,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/450\/revisions\/530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/620"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Investigador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")